<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43422">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756625</url>
  </required_header>
  <id_info>
    <org_study_id>PREMIUM</org_study_id>
    <nct_id>NCT01756625</nct_id>
  </id_info>
  <brief_title>PREMIUM, Observational Study</brief_title>
  <official_title>Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr.Laurent Mineur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BESPIM, CHU Nîmes (data analysis)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Sainte Catherine</source>
  <oversight_info>
    <authority>France : CCTIRS / CNIL</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective
      cohort study and with independent investigators. The purpose is to compare PFS in real life
      with PFS clinical trials and to determine factors impacting efficacy and compliance to
      cetuximab treatment in first line K-ras wild-type (wt) metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective studies have shown the influence of some factors on the efficacy of treatment
      with cetuximab (nicotine, magnesium etc..). No randomized study has compared the mode of
      administration of weekly and biweekly cetuximab. What are the factors influencing patient
      compliance? Adverse events, the relation between doctor and patient. PREMIUM will attempt to
      explore and assess the variables associated with efficacy and compliance to treatment and
      study practices in France for clinical management.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To compare PFS rate at 1 year with PFS in clinical studies (ITT and subgroup analysis)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR at 1 year (ITT and subgroup analysis)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>First Line WT KRAS mCRC</condition>
  <arm_group>
    <arm_group_label>First line WT KRAS mCRC</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients from private and public centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt; 18 years old diagnosed with mCRC

          -  patients naïve for CT excepted for adjuvant setting or trated max 2 cycles CT in
             first line mCRC with or without cetuximab

          -  all patients receiving cetuximab in first line treatment associated or not with CT

          -  patients relapsed &lt; 6 months after an adjuvant therapy

        Exclusion Criteria:

          -  patients participating to clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <state>Vaucluse</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 20, 2012</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut Sainte Catherine</investigator_affiliation>
    <investigator_full_name>Dr.Laurent Mineur</investigator_full_name>
    <investigator_title>Oncologist</investigator_title>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>nicotine</keyword>
  <keyword>magnesium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
